Imagindairy And Ginkgo Bioworks Partner To Develop Animal-Free Non-Whey Dairy Proteins

RTTNews | 371 dias atrás
Stocktwits
Imagindairy And Ginkgo Bioworks Partner To Develop Animal-Free Non-Whey Dairy Proteins

(RTTNews) - Israeli-based foodtech company Imagindairy and Ginkgo Bioworks (DNA) announced Tuesday a new partnership with the aim to deliver a global solution for animal-free non-whey dairy protein production in a highly cost-effective manner.

This collaboration will leverage Ginkgo Protein Expression Services and Imagindairy's process development and scale-up expertise to accelerate the development of functional non-whey dairy proteins.

This is a multi-year program, funded in part by a joint grant from the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation.

Imagindairy and Ginkgo have partnered to design an optimized organism capable of cost-effectively producing non-whey dairy proteins. This will allow Imagindairy to remain focused on whey protein production and commercialization while accelerating time to market of non-whey proteins.

Marcadores : DNA
Stocktwits
read more
Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, announced Thursday the acquisition of microbial innovation firm AgBiome, Inc.'s platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline.
RTTNews | 355 dias atrás
Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference later on Wednesday, Ginkgo Bioworks (DNA) said it expects to meet its previously disclosed new program and revenue guidance ranges in 2023, based on its preliminary unaudited estimates.
RTTNews | 447 dias atrás
Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Cell programming firm Ginkgo Bioworks Holdings, Inc. (DNA) and biotechnology company Zymergen, Inc. (ZY) announced Monday they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization.
RTTNews | 981 dias atrás
Asian Markets Trade Mostly Higher

Asian Markets Trade Mostly Higher

Asian stock markets are trading mostly higher on Wednesday, following the mixed cues from Wall Street overnight, as traders remain cautious as uncertainty prevails over the size and the scope of new reciprocal tariffs on imports to the US to be announced later in the day. Some traders also continue to pick up stocks at a bargain after heavy selling in the previous sessions.
RTTNews | 5h 32min atrás
Ferramentas
Calendário Econômico
Market Hours
Interest Rates
Holidays Calendar
Mercado Forex
Volatilidade no Forex
Correlação no Forex
Notícias sobre Forex
forex analysis
Dados do COT
Liquidez
Calculadoras Forex
Mapa do Calor do Forex
Indicators Heatmap
Comunidade
Comunidade
Sistemas
Sistemas Mais Populares
Estratégias
Concursos
Gráficos de Forex
Sentimento do Forex
Indicador de Perspectivas
Análises
Corretoras
Prop Trading Firms
Serviços de VPS
Provedores de Sinais
Serviços de Programação de EA
Affiliate Programs
Serviços de Corretora PAMM
Serviços de Programa de Reembolso
Plataformas de Trading
Expert Advisors
Exchanges de Criptomoedas
Trading Courses
Corretoras
Spreads das Corretoras de Forex
Cotações de Corretoras de Forex
Swaps de Corretoras de Forex
Volume da Corretora de Forex
Promoções de Corretoras de Forex Press Release
Plataforma
Widgets
Recursos
API
RSS
Stock Portfolio
Affiliate Software
Gráficos Avançados
Assistência
Perguntas Frequentes
Ajuda
Entre em contato conosco
Relatar um erro!
Sobre
Blog
© 2025 Myfxbook Ltd. Todos os Direitos Reservados.
AVISO DE ALTO RISCO: A negociação no mercado de câmbio traz consigo um alto nível de risco que pode não ser adequado para qualquer investidor. A alavancagem cria exposição adicional a riscos e perdas. Antes de decidir negociar no mercado de câmbio, considere cuidadosamente seus objetivos de investimento, seu nível de experiência e sua tolerância ao risco. Você pode perder parte de seu investimento inicial ou todo ele. Não invista um dinheiro que você não tem condições de perder. Informe-se sobre os riscos associados à negociação no mercado de câmbio e procure o conselho de um consultor financeiro ou fiscal independente, caso tenha alguma dúvida. Quaisquer dados e informações são fornecidos "como estão" exclusivamente para fins informativos. Eles não se destinam a fins comerciais ou de aconselhamento. O desempenho passado não é indicativo de resultados futuros.